Linghong Huang

Linghong Huang

Auto-generated profile, based on publicly available information

Linghong Huang

Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 September 2022 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
LHLinghong Huang
Linghong Huang
ZLZonghua Liu
Zonghua Liu
CWChongjie Wu
Chongjie Wu
JLJiansheng Lin
Jiansheng Lin
NLNing Liu
Ning Liu
Dendritic cells (DCs)‐based tumor vaccines have the advantages of high safety and rapid activation of T cells, and have been approved for clinical tumor treatment. However, the conventional DC vaccines have some severe problems, such as poor activation of DCs in vitro, low level of antigen presentation, reduced cell viability, and difficulty in targeting lymph nodes in vivo, resulting in poor clinical therapeutic effects. In this research, magnetic nanoparticles Fe3O4@Ca/MnCO3 were prepared and used to actively and efficiently deliver antigens to the cytoplasm of DCs, promote antigen cross‐presentation and DC activation, and finally enhance the cellular immune response of DC vaccines. The results show that the magnetic nanoparticles can actively and quickly deliver antigens to the cytoplasm of DCs by regulating the magnetic field, and achieve cross‐presentation of antigens. At the same time, the nanoparticles degradation product Mn2+ enhanced immune stimulation through the interferon gene stimulating protein (STING) pathway, and another degradation product Ca2+ ultimately promoted cellular immune response by increasing autophagy. The DC vaccine constructed with the magnetic nanoparticles can more effectively migrate to the lymph nodes, promote the proliferation of CD8+ T cells, prolong the time of immune memory, and produce higher antibody levels. Compared with traditional DC vaccines, cytoplasmic antigen delivery with the magnetic nanoparticles provides a new idea for the construction of novel DC vaccines.

3 March 2025 in Biomaterials
Verified
Journal Article
Closed access
TSTing Song
Ting Song
NLNan Li
Nan Li
QZQinhua Zuo
Qinhua Zuo
LHLinghong Huang
Linghong Huang
ZLZonghua Liu
Zonghua Liu
ZGZhong Guo
Zhong Guo

24 January 2025 in Materials Today Bio
Verified
Journal Article
Open access
LHLinghong Huang
Linghong Huang
XSXin-yuan Sun
Xin-yuan Sun
QZQinhua Zuo
Qinhua Zuo
TSTing Song
Ting Song
NLNing Liu
Ning Liu
WXWei Xue
Wei Xue
Bromodomain-containing protein 4 (BRD4) is a key protein that drives the development of malignant melanoma and is closely associated with the ferroptosis signaling pathway. Degradation of BRD4 can downregulate the expression of ferroptosis-related genes such as GPX4, thereby promoting tumor-specific ferroptosis. Therefore, targeting BRD4 for degradation is a promising strategy for inhibiting tumor growth. We constructed a PROTAC drug-based tumor antigen capture system to protect the activity of antigen-presenting cells (APCs) and promote antigen capture. The selected PROTAC drug (ARV-825) can specifically degrade BRD4 without harming immune cells. Specifically, magnetic nanoclusters (MNC) coated with calcium-doped manganese carbonate (Ca/MnCO3), were used to load PROTAC drug (ARV-825) and anti-PD1, forming the MNC@Ca/MnCO3/ARV/anti-PD1 system. ARV-825 can specifically degrade BRD4 and GPX4, significantly inducing ferroptosis in tumor cells and releasing tumor-associated antigens. The MNC@Ca/MnCO3 particles, with their large specific surface area, adsorbed the tumor antigens, preventing antigen loss and enhancing antigen presentation. Additionally, Mn2+ served as an adjuvant to promote the maturation and cross-presentation of APCs. Together with the PD1 antibody, this further enhanced the anti-tumor response of the in situ tumor vaccine and reversed the suppressive immune microenvironment. This antigen capture system provides a novel strategy to improve the anti-tumor efficacy of in situ tumor vaccines.

7 May 2024 in Chemical Engineering Journal
Verified
Journal Article
Closed access
JLJiansheng Lin
Jiansheng Lin
XCXin Cui
Xin Cui
ZLZonghua Liu
Zonghua Liu
YJYideng Jiang
Yideng Jiang
LHLinghong Huang
Linghong Huang

23 March 2025 in Nano Today
Verified
Journal Article
Closed access
LHLinghong Huang
Linghong Huang
XSXinyuan Sun
Xinyuan Sun
TSTing Song
Ting Song
JLJun Long
Jun Long
XCXuewu Chen
Xuewu Chen
ZGZhong Guo
Zhong Guo